First PREMIER Bank Decreases Holdings in Pfizer Inc. (NYSE:PFE)

First PREMIER Bank decreased its position in shares of Pfizer Inc. (NYSE:PFE) by 46.2% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 36,140 shares of the biopharmaceutical company’s stock after selling 31,013 shares during the quarter. First PREMIER Bank’s holdings in Pfizer were worth $1,045,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Olistico Wealth LLC purchased a new stake in shares of Pfizer during the 2nd quarter worth approximately $25,000. MFA Wealth Advisors LLC purchased a new stake in shares of Pfizer during the 2nd quarter worth approximately $29,000. Quarry LP purchased a new stake in shares of Pfizer during the 2nd quarter worth approximately $31,000. Creekmur Asset Management LLC acquired a new position in shares of Pfizer during the 4th quarter worth approximately $32,000. Finally, Trivant Custom Portfolio Group LLC raised its position in shares of Pfizer by 100.0% during the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock worth $33,000 after purchasing an additional 600 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

PFE has been the subject of several research reports. StockNews.com upgraded Pfizer from a “hold” rating to a “buy” rating in a research report on Wednesday. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research report on Thursday, October 3rd. UBS Group lifted their price objective on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 31st. Barclays lifted their price objective on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Finally, Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Eight equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Pfizer presently has an average rating of “Moderate Buy” and an average price target of $34.54.

Pfizer Trading Up 0.7 %

PFE stock opened at $29.39 on Wednesday. The company has a market cap of $166.54 billion, a price-to-earnings ratio of -486.33, a PEG ratio of 1.23 and a beta of 0.67. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65. The business has a fifty day simple moving average of $29.09 and a 200-day simple moving average of $28.35. Pfizer Inc. has a 52 week low of $25.20 and a 52 week high of $33.92.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. The business had revenue of $13.28 billion during the quarter, compared to the consensus estimate of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The business’s revenue for the quarter was up 2.1% on a year-over-year basis. During the same period in the prior year, the firm posted $0.67 EPS. On average, equities research analysts expect that Pfizer Inc. will post 2.66 EPS for the current year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.